CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Corvus Pharmaceuticals, Inc. - CRVS CFD

1.7747
1.13%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.0306
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Corvus Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.7647
Open* 1.7047
1-Year Change* 170.03%
Day's Range* 1.7047 - 1.8047
52 wk Range 0.61-4.19
Average Volume (10 days) 280.41K
Average Volume (3 months) 4.86M
Market Cap 97.59M
P/E Ratio -100.00K
Shares Outstanding 49.04M
Revenue N/A
EPS -0.64
Dividend (Yield %) N/A
Beta 1.04
Next Earnings Date Mar 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 1.7647 0.0600 3.52% 1.7047 1.8147 1.7047
Mar 26, 2024 1.7547 -0.0200 -1.13% 1.7747 1.8347 1.7547
Mar 25, 2024 1.7447 0.0000 0.00% 1.7447 1.8147 1.7047
Mar 22, 2024 1.7547 -0.0500 -2.77% 1.8047 1.8247 1.6847
Mar 21, 2024 1.7947 -0.1100 -5.78% 1.9047 1.9147 1.7847
Mar 20, 2024 1.8247 -0.0900 -4.70% 1.9147 1.9247 1.8147
Mar 19, 2024 1.9547 0.0600 3.17% 1.8947 1.9747 1.8947
Mar 18, 2024 1.8947 -0.0100 -0.53% 1.9047 1.9847 1.8747
Mar 15, 2024 1.9047 0.0100 0.53% 1.8947 1.9747 1.8747
Mar 14, 2024 1.8847 -0.1100 -5.51% 1.9947 2.0047 1.7947
Mar 13, 2024 1.9947 0.0000 0.00% 1.9947 2.0647 1.9947
Mar 12, 2024 2.0147 0.0400 2.03% 1.9747 2.0647 1.8247
Mar 11, 2024 1.9747 -0.1800 -8.35% 2.1547 2.1647 1.9447
Mar 8, 2024 2.1147 -0.1800 -7.84% 2.2947 2.3147 2.0747
Mar 7, 2024 2.2447 0.1500 7.16% 2.0947 2.3147 2.0547
Mar 6, 2024 2.1447 0.0500 2.39% 2.0947 2.1547 2.0647
Mar 5, 2024 2.0847 -0.0500 -2.34% 2.1347 2.1447 1.9947
Mar 4, 2024 2.1347 -0.0600 -2.73% 2.1947 2.2347 2.1347
Mar 1, 2024 2.1747 -0.0400 -1.81% 2.2147 2.2547 2.1447
Feb 29, 2024 2.2347 -0.0600 -2.61% 2.2947 2.3347 2.2047

Corvus Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Monday, May 6, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Corvus Pharmaceuticals Inc Earnings Release
Q1 2024 Corvus Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Friday, June 14, 2024

Time (UTC)

20:00

Country

US

Event

Corvus Pharmaceuticals Inc Annual Shareholders Meeting
Corvus Pharmaceuticals Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Total Operating Expense 32.565 38.63 6.301 48.854 49.222
Selling/General/Admin. Expenses, Total 8.097 9.515 11.93 10.879 10.636
Research & Development 24.468 29.115 31.83 37.975 38.586
Operating Income -32.565 -38.63 -6.301 -48.854 -49.222
Interest Income (Expense), Net Non-Operating -9.351 -4.846 0.306 2.182 2.283
Net Income Before Taxes -41.307 -43.241 -5.995 -46.672 -46.939
Net Income After Taxes -41.307 -43.241 -5.995 -46.672 -46.939
Net Income Before Extra. Items -41.307 -43.241 -5.995 -46.672 -46.939
Net Income -41.307 -43.241 -5.995 -46.672 -46.939
Income Available to Common Excl. Extra. Items -41.307 -43.241 -5.995 -46.672 -46.939
Income Available to Common Incl. Extra. Items -41.307 -43.241 -5.995 -46.672 -46.939
Diluted Net Income -41.307 -43.241 -5.995 -46.672 -46.939
Diluted Weighted Average Shares 46.5535 41.8541 29.4789 29.3498 27.51
Diluted EPS Excluding Extraordinary Items -0.8873 -1.03314 -0.20337 -1.5902 -1.70625
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -0.88777 -1.03314 -1.47407 -1.5902 -1.70625
Unusual Expense (Income) 0 0 -37.459
Other, Net 0.587 0.235
Gain (Loss) on Sale of Assets 0.022
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 5.622 6.574 5.666 12.473 7.013
Selling/General/Admin. Expenses, Total 1.654 1.98 1.586 2.108 2.09
Research & Development 3.968 4.594 4.08 10.365 4.923
Operating Income -5.622 -6.574 -5.666 -12.473 -7.013
Interest Income (Expense), Net Non-Operating -0.881 -1.355 -4.32 -2.505 -1.496
Net Income Before Taxes -6.503 -7.873 -9.816 -14.831 -8.363
Net Income After Taxes -6.503 -7.873 -9.816 -14.831 -8.363
Net Income Before Extra. Items -6.503 -7.873 -9.816 -14.831 -8.363
Net Income -6.503 -7.873 -9.816 -14.831 -8.363
Income Available to Common Excl. Extra. Items -6.503 -7.873 -9.816 -14.831 -8.363
Income Available to Common Incl. Extra. Items -6.503 -7.873 -9.816 -14.831 -8.363
Diluted Net Income -6.503 -7.873 -9.816 -14.831 -8.363
Diluted Weighted Average Shares 47.4974 46.5562 46.5535 46.5535 46.5535
Diluted EPS Excluding Extraordinary Items -0.13691 -0.16911 -0.21085 -0.31858 -0.17964
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.13691 -0.16911 -0.21133 -0.31858 -0.17964
Other, Net 0 0.056 0.148 0.147 0.146
Unusual Expense (Income) 0
Gain (Loss) on Sale of Assets 0.022
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 43.664 71.312 45.336 79.344 115.589
Cash and Short Term Investments 42.303 69.451 44.259 77.982 114.597
Cash & Equivalents 13.159 63.458 16.455 5.154 39.196
Short Term Investments 29.144 5.993 27.804 72.828 75.401
Total Receivables, Net 0.633 0.539 0.086 0.329 0.337
Prepaid Expenses 0.626 1.194 0.585 0.547 0.39
Other Current Assets, Total 0.102 0.128 0.406 0.486 0.265
Total Assets 68.24 109.455 85.529 83.646 118.232
Property/Plant/Equipment, Total - Net 2.57 3.641 2.554 3.789 2.18
Property/Plant/Equipment, Total - Gross 7.116 7.893 6.346 6.949 4.597
Accumulated Depreciation, Total -4.546 -4.252 -3.792 -3.16 -2.417
Other Long Term Assets, Total 0.129 0.236 0.414 0.513 0.463
Total Current Liabilities 10.752 9.692 12.149 10.225 7.027
Accounts Payable 1.976 1.565 3.467 2.448 1.998
Accrued Expenses 8.776 8.127 8.682 7.777 4.869
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.16
Total Liabilities 12.125 12.293 13.381 12.535 7.896
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 1.373 2.601 1.232 2.31 0.869
Total Equity 56.115 97.162 72.148 71.111 110.336
Redeemable Preferred Stock 0 0
Common Stock 0.005 0.005 0.003 0.003 0.003
Additional Paid-In Capital 364.361 361.669 295.281 288.224 280.84
Retained Earnings (Accumulated Deficit) -307.688 -266.381 -223.14 -217.145 -170.473
Other Equity, Total -0.563 1.869 0.004 0.029 -0.034
Total Liabilities & Shareholders’ Equity 68.24 109.455 85.529 83.646 118.232
Total Common Shares Outstanding 46.5535 46.5535 28.3726 27.9532 29.3239
Long Term Investments 21.877 34.266 37.225
Accounts Receivable - Trade, Net 0.588 0.507
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 33.094 37.91 35.551 43.664 51.272
Cash and Short Term Investments 32.168 37.017 34.467 42.303 49.617
Cash & Equivalents 20.105 7.658 9.654 13.159 24.588
Short Term Investments 12.063 29.359 24.813 29.144 25.029
Total Receivables, Net 0.05 0.034 0.467 0.633 0.534
Prepaid Expenses 0.662 0.723 0.486 0.626 0.724
Other Current Assets, Total 0.214 0.136 0.131 0.102 0.397
Total Assets 51.942 58.041 58.197 68.24 80.348
Property/Plant/Equipment, Total - Net 1.687 1.985 2.283 2.57 2.914
Property/Plant/Equipment, Total - Gross 6.356 6.624 6.886 7.116 7.44
Accumulated Depreciation, Total -4.669 -4.639 -4.603 -4.546 -4.526
Long Term Investments 17.072 18.017 20.234 21.877 25.914
Other Long Term Assets, Total 0.089 0.129 0.129 0.129 0.248
Total Current Liabilities 7.299 7.858 8.29 10.752 13.978
Accounts Payable 1.404 2.098 1.407 1.976 4.227
Accrued Expenses 5.895 5.76 6.883 8.776 9.751
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 7.653 8.558 9.33 12.125 15.667
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.354 0.7 1.04 1.373 1.689
Total Equity 44.289 49.483 48.867 56.115 64.681
Common Stock 0.005 0.005 0.005 0.005 0.005
Additional Paid-In Capital 373.791 372.91 364.857 364.361 363.741
Retained Earnings (Accumulated Deficit) -328.064 -322.064 -315.561 -307.688 -297.872
Other Equity, Total -1.443 -1.368 -0.434 -0.563 -1.193
Total Liabilities & Shareholders’ Equity 51.942 58.041 58.197 68.24 80.348
Total Common Shares Outstanding 49.0386 48.8984 46.5685 46.5535 46.5535
Accounts Receivable - Trade, Net 0.011 0 0.429 0.588 0.503
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -41.307 -43.241 -5.995 -46.672 -46.939
Cash From Operating Activities -27.023 -36.715 -34.778 -37.321 -40.988
Cash From Operating Activities 0.367 0.46 0.632 0.743 0.847
Non-Cash Items 12.505 9.302 -31.324 6.704 6.527
Changes in Working Capital 1.412 -3.236 1.909 1.904 -1.423
Cash From Investing Activities -23.276 21.56 44.769 3.255 -30.192
Capital Expenditures -0.269 -0.005 -0.076 -0.025 -0.355
Other Investing Cash Flow Items, Total -23.007 21.565 44.845 3.28 -29.837
Cash From Financing Activities 0 62.158 1.31 0.024 65.27
Financing Cash Flow Items
Issuance (Retirement) of Stock, Net 0 62.158 1.31 0.024 65.27
Net Change in Cash -50.299 47.003 11.301 -34.042 -5.91
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -7.873 -41.307 -31.491 -16.66 -8.297
Cash From Operating Activities -8.111 -27.023 -19.476 -12.547 -6.424
Cash From Operating Activities 0.057 0.367 0.273 0.179 0.087
Non-Cash Items 1.959 12.505 7.451 4.146 1.835
Changes in Working Capital -2.254 1.412 4.291 -0.212 -0.049
Cash From Investing Activities 4.602 -23.276 -19.394 -22.434 -25.574
Other Investing Cash Flow Items, Total 4.636 -23.007 -19.125 -22.43 -25.574
Cash From Financing Activities 0.004 0 0 0
Issuance (Retirement) of Stock, Net 0.004 0 0 0
Net Change in Cash -3.505 -50.299 -38.87 -34.981 -31.998
Capital Expenditures -0.034 -0.269 -0.269 -0.004

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Corvus Pharmaceuticals, Inc. Company profile

About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which is engaged in the development and commercialization of precisely targeted oncology therapies. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression; and CPI-935, Adenosine A2B Receptor Antagonist.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Corvus Pharmaceuticals Inc revenues was not reported. Net loss increased from $6M to $43.2M. Higher net loss reflects Gain on deconsolidation of Angel Pharmac decrease from $37.5M (income) to $0K, Loss from equity method investment increase from $234K to $4.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.20 to -$1.03.

Industry: Biotechnology & Medical Research (NEC)

863 Mitten Rd Ste 102
BURLINGAME
CALIFORNIA 94010-1311
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

US100

18,264.10 Price
+0.000% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

3,575.25 Price
+1.670% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

70,937.05 Price
+2.740% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,219.29 Price
+1.130% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading